Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 24668415)

1.
2.

Concentrations of IGF-I and IGFBP-3 and brain tumor risk in the European Prospective Investigation into Cancer and Nutrition.

Rohrmann S, Linseisen J, Becker S, Allen N, Schlehofer B, Overvad K, Olsen A, Tjønneland A, Melin BS, Lund E, Vineis P, Grioni S, Tumino R, Palli D, Mattiello A, Bonet C, Chirlaque MD, Sánchez MJ, Rodríguez L, Dorronsoro M, Ardanaz E, Lagiou P, Trichopoulou A, Trichopoulos D, Dossus L, Grote VA, Boeing H, Aleksandrova K, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Khaw KT, Wareham NJ, Key TJ, Rinaldi S, Romieux I, Gallo V, Michaud DS, Riboli E, Kaaks R.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2174-82. doi: 10.1158/1055-9965.EPI-11-0179. Epub 2011 Jul 25.

3.

Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults.

Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB, Psaty BM.

J Am Geriatr Soc. 2008 Apr;56(4):652-60. doi: 10.1111/j.1532-5415.2007.01637.x. Epub 2008 Feb 27.

PMID:
18312313
4.

Insulin-like growth factor-I, IGF binding protein-3, and breast cancer in young women: a comparison of risk estimates using different peptide assays.

Rinaldi S, Kaaks R, Zeleniuch-Jacquotte A, Arslan AA, Shore RE, Koenig KL, Dossus L, Riboli E, Stattin P, Lukanova A, Toniolo P.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):48-52.

5.

Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.

Lin Y, Jiang T, Zhou K, Xu L, Chen B, Li G, Qiu X, Jiang T, Zhang W, Song SW.

Neuro Oncol. 2009 Oct;11(5):468-76. doi: 10.1215/15228517-2008-114. Epub 2009 Jan 22.

6.

Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer.

Baglietto L, English DR, Hopper JL, Morris HA, Tilley WD, Giles GG.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):763-8.

7.

Serum levels of insulin-like growth factor-I and insulin-like growth factor-I binding protein-3: quality control for studies of stored serum.

Berrigan D, Potischman N, Dodd KW, Nicar M, McQuillan G, Lavigne JA, Barrett JC, Ballard-Barbash R.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):1017-22.

8.

Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.

Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E.

Cancer Causes Control. 2005 Apr;16(3):255-62.

PMID:
15947877
9.

Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.

Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.

Cancer Res. 2003 Jul 15;63(14):3991-4.

10.

Glioma risk in relation to serum levels of insulin-like growth factors.

Lönn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D.

Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):844-6.

11.

Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies.

Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C, Palli D, Tumino R, Vineis P, Peeters PH, van Gils CH, Bueno-de-Mesquita BH, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer J, Borgquist S, Dumeaux V, Torhild Gram I, Lund E, Trichopoulou A, Makrygiannis G, Benetou V, Molina E, Donate Suárez I, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM, Olsen A, Tjonneland A, Grønbaek H, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Slimani N, Boffetta P, Jenab M, Riboli E, Kaaks R.

Int J Cancer. 2010 Apr 1;126(7):1702-15. doi: 10.1002/ijc.24927.

PMID:
19810099
12.

Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004.

Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E.

Int J Cancer. 2011 Feb 1;128(3):660-7. doi: 10.1002/ijc.25381.

13.

Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.

Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X.

J Natl Cancer Inst. 1999 Jan 20;91(2):151-6.

14.

Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk.

Schernhammer ES, Holly JM, Pollak MN, Hankinson SE.

Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):699-704.

15.

The insulin-like growth factor system and mammographic features in premenopausal and postmenopausal women.

dos Santos Silva I, Johnson N, De Stavola B, Torres-Mejía G, Fletcher O, Allen DS, Allen NE, Key TJ, Fentiman IS, Holly JM, Peto J.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):449-55.

16.

Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II.

Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE.

Endocr Relat Cancer. 2006 Jun;13(2):583-92.

17.

Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition.

Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Grønbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quirós JR, Ardanaz E, Navarro C, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R.

Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1121-7.

18.

Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: A nested case-control study in large scale cohort study in Japan.

Mikami K, Ozasa K, Nakao M, Miki T, Hayashi K, Watanabe Y, Mori M, Sakauchi F, Washio M, Kubo T, Suzuki K, Wakai K, Nakachi K, Tajima K, Ito Y, Inaba Y, Tamakoshi A; JACC Study Group.

Asian Pac J Cancer Prev. 2009 Dec;10 Suppl:57-61.

19.

STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma.

Thota B, Arimappamagan A, Kandavel T, Shastry AH, Pandey P, Chandramouli BA, Hegde AS, Kondaiah P, Santosh V.

J Neurosurg. 2014 Aug;121(2):374-83. doi: 10.3171/2014.4.JNS131198. Epub 2014 May 30.

PMID:
24878287
20.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.

J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk